Media ReleasesInnate Immunotherapeutics

View All Innate Immunotherapeutics News


Innate Immunotherapeutics Limited, 4C Quarterly Cash Flow Report

Innate Immunotherapeutics Limited (ASX Code: IIL) has today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2016.
 
The cash balance as at 31 March 2016 was $3,264,000, a decrease of $1,880,000 from the end of the previous quarter.
 
Net cash usage for the three months was $1,997,000 of which $1,395,000 related to research and development, being principally the Company's Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS).
 
 
For further information please download PDF attached:
Download this document